December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.44 -0.81 (-0.53%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
55 56 Next >
News headline image
Novartis Reports Q3 Momentum, But Shares Lose Support ↗
Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook. 
Via Investor's Business Daily
News headline image
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. 
Via Investor's Business Daily
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗
Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions. 
Via Benzinga
News headline image
3 Absurdly Cheap Stocks That Pay High Dividends ↗
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
News headline image
Looking Into Novartis's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why NYSE:NVS is a Top Pick for Dividend Investors. ↗
Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics. 
Via Chartmill
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals. 
Via Chartmill
News headline image
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
News headline image
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European... 
Via Benzinga
News headline image
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move ↗
Novartis is taking a more calculated and strategic approach to its growth. 
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
News headline image
2 Magnificent Dividend Stocks to Buy and Hold Forever ↗
These companies have compelling track records. 
Via The Motley Fool
News headline image
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm ↗
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting... 
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
News headline image
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear ↗
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
The Importance of Managing Bad Cholesterol: What You Should Know
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation 
Via Brandpoint
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... 
Via Benzinga
Topics Intellectual Property
News headline image
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... 
Via Benzinga
News headline image
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.